Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study

Unknown Phase 2 NCT04055909

Study Description

This is a randomized, double-blind, placebo-controlled dose-selection study in which two doses of nangibotide are tested versus placebo.

Study Details

Registry ID:
NCT04055909
Conditions:
Shock, Septic
Phase:
Phase 2
Target Enrollment:
355 participants
Start Date:
Healthy Volunteers:
No

Study Locations (64 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →